Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
BETAHISTINE DIHYDROCHLORIDE
Abbott Healthcare Products Ltd
8 Milligram
Tablets
2008-12-12
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Betahecon 8 mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 8 mg betahistine dihydrochloride. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Tablet A white, round, flat tablet, imprinted ‘256' on one face. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS In the management of vertigo, tinnitus and hearing loss associated with Ménière's syndrome. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _Adults (including the elderly): _The usual daily dose is 8 to 16 mg three times daily taken preferably with meals. Maintenance doses are generally in the range 24-48 mg daily. _Children: _Not applicable. 4.3 CONTRAINDICATIONS Use concurrently with antihistamines. Use in children. Use in phaeochromocytoma. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Caution is advised in the treatment of patients with a history of peptic ulcer. Clinical intolerance to betahistine in bronchial asthma patients has been shown in a relatively few patients and therefore caution should be exercised when administering betahistine to patients with bronchial asthma. 4.5 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION Although an antagonism between betahistine and antihistamines could be expected on a theoretical basis, no such interactions have been reported. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 26/09/2011_ _CRN 2105795_ _page number: 1_ 4.6 FERTILITY, PREGNANCY AND LACTATION High dosage animal tests have shown no teratogenic properties, but the usual precautions should be observed when administering betahistine to patients during pregnancy. Betahistine does not accumulate in fat and has a Read the complete document